March 22, 2019 | Announcements
GCA Advises Hitachi Chemical on the Acquisition of Apceth Biopharma From Santo Holding
GCA is pleased to announce we advised Hitachi Chemical, a global leader in the production and distribution of functional materials and advanced components, on the acquisition of Apceth Biopharma, a contract manufacturer of regenerative medicine products, from Santo Holding.
Hitachi Chemical’s regenerative medicine division operates primarily in the United States and Japan. Apceth Biopharma operates production sites in Germany, manufacturing regenerative medicine products on contract for European and American pharmaceutical companies.
The acquisition of Apceth expands Hitachi Chemical’s footprint into Europe, the world’s second-largest market for regenerative medicine. Additionally, this acquisition enables Hitachi Chemical to manufacture and distribute regenerative medicine products on a truly global scale as the company aims to secure a leading share of the global market for contract manufacturing of regenerative medicine products.
GCA acted as exclusive financial advisor to Hitachi Chemical in connection with this transaction.
GCA is a global investment bank that provides strategic M&A and capital markets advisory services to growth companies and market leaders. The firm offers worldwide coverage with over 400 professionals in 21 offices across America, Asia and Europe. Built by the people that run the business, GCA is a firm of experts who focus on deals that require commitment, original perspective, skill and exceptional networks. Learn more at www.gcaglobal.com.